Analysts think NKTR stock price could increase by 94%
Oct 22, 2024, 11:25 AM
-28.06%
What does NKTR do
Nektar Therapeutics, a San Francisco-based biopharmaceutical company with 137 employees, focuses on developing immunotherapy medicines for oncology and immunology, including NKTR-255 and Rezpegaldesleukin. Its pipeline targets immune response pathways to address cancer and autoimmune conditions.
4 analysts think NKTR stock price will increase by 94.46%. The current median analyst target is $2.70 compared to a current stock price of $1.39. The lowest analysts target is $1.31 and the highest analyst target is $4.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
